Bilr 355 clinical trials
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses bilr 355 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2005 (4)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2005 | 4 |
| 2006 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
5,11-dihydro-11-ethyl-5-methyl-8-(2-(1-oxido-4-quinolinyl)ethyl)-6H-dipyrido(3,2-B,2',3'-E)(1,4)diazepin-6-one (8) · Ritonavir (4) · Lamivudine, zidovudine drug combination (1) · Lopinavir-ritonavir drug combination (1) · Tipranavir (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Solutions (1)
Studies
Open first, then newest update. How each study uses bilr 355 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer SubjectsCompletedPhase 1Boehringer IngelheimNCT02259868Written as BILR 355 BS - Suspension low dose
- Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy SubjectsCompletedPhase 1Boehringer IngelheimNCT02256774Written as BILR 355 BS
- Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy SubjectsCompletedPhase 1Boehringer IngelheimNCT02256826Written as BILR 355 BS
- Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02257021Written as BILR 355 BS
- Pharmacokinetics and Safety of BILR 355 in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02253940Written as BILR 355 - Treatment A (current tablet formulation)
- Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02253901Written as BILR 355 BS
- Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02253914Written as BILR 355 BS, solution
- Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated PatientsTerminatedPhase 2Boehringer IngelheimNCT00294372Written as BILR 355 BS
Given beside what is tested · 4 — bilr 355 is usual care or a partner of the new treatment
- Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02257008Written as BILR 355 BS
- A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02254538Written as BILR 355 BS
- Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02253927Written as BILR 355 - D1
- Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02253953Written as BILR 355 BS, D1
Codes
What other systems call bilr 355 · ClinicalTrials.gg INT033092
- Wikidata Q83063978BILR 355One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q83063978 | BILR 355 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.